Background: A third dose of measles-mumps-rubella vaccine (MMR) may be administered for various reasons, but data on long-term immunity are limited. We assessed neutralizing antibody levels against measles and rubella among adults up to 11 years after receipt of a third MMR dose. Methods: In this longitudinal study, healthy adults who received a third MMR dose as young adults (ages 18–28 years) were recalled around 5 years and 9–11 years after the third dose. Measles and rubella antibody levels were assessed by plaque-reduction and immunocolorimetric neutralization assays, respectively. Antibody concentrations <120 mIU/mL and <10 U/mL were considered potentially susceptible to measles and rubella, respectively. Geometric mean concentrations (GMCs) and 95% confidence intervals (CIs) over time were estimated from generalized estimating equation models. Results: Approximately 5 and 9–11 years after receipt of the third dose, 405 and 304 adults were assessed, respectively. Measles GMC was 428 mIU/mL (95% CI, 392–468 mIU/mL) 5 years postvaccination, declining to 381 mIU/mL (95% CI, 339–428 mIU/mL) 11 years postvaccination. At the last follow-up visit (9–11 years postvaccination), 10% of participants were potentially susceptible to measles infection. Rubella GMCs were stable throughout the follow-up period (63 U/mL to 65 U/mL); none of the participants was susceptible to rubella at the last follow-up visit. Conclusions: Eleven years after receiving a third MMR dose, measles and rubella neutralizing antibody levels remained high in adults. However, on the basis of waning antibody levels, some adults may become susceptible to measles infection over time despite receipt of 3 vaccine doses.
11 June 2025 in Human Vaccines & Immunotherapeutics
Human papillomavirus (HPV) vaccination coverage in the US is lower than other recommended adolescent vaccines. Coverage is consistently lower in rural areas, compared to urban areas. Despite this, there exists relatively little evidence on perspectives of HPV vaccination during adolescence/young adulthood. We conducted 56 interviews with young adults about their experiences, perspectives, and decision-making with HPV vaccination. Young adults aged 18–21 years who, as adolescents, may have initially refused or delayed (or their parents may have refused or delayed) and subsequently accepted HPV vaccination who resided in rural Wisconsin or urban Minnesota were eligible to participate. Interviews included questions and prompts about decision-making processes and perspectives about HPV vaccination, such as “How did you feel about the HPV vaccine before you got vaccinated?” and “What changes happened that factored into you getting the shot?” In a thematic analysis, young adults valued: information-gathering about vaccines, the opportunity to make vaccine decisions on their own (or with support of parents), and a trusting relationship with their healthcare provider. They expressed a wide range of perspectives on vaccine acceptance and hesitancy. Young adults were more concerned about needles, pain, and discomfort than other adverse outcomes following vaccination. A higher proportion of young adults in urban areas (compared to rural areas) mentioned the importance of trust in their healthcare provider. Strategies to increase HPV vaccine uptake and acceptance may consider young adults’ perspectives, including the importance of the information-gathering process and relationships with their healthcare providers.
24 June 2026 in Cancer Epidemiology, Biomarkers & Prevention
Background: Public health emergencies can substantially affect routine health care. Large cancer screening declines during the early months of the COVID-19 pandemic are well documented; however, COVID-19’s impact on follow-up of abnormal screening exams and cancer diagnoses is less reported. We examined the impacts of COVID-19 on the cervical, colorectal, and lung cancer screening processes, within 10 health systems in the Population-based Research to Optimize the Screening Process (PROSPR) consortium. Methods: PROSPR data were used to calculate: (i) monthly rates of cancer testing and, for pre-COVID and COVID time periods, (ii) proportions of individuals receiving recommended follow-up within 6 months of an abnormal test, and (iii) cancer incidence. Surveys were used to assess the healthcare systems’ local context. Results: During the first 2 months of the pandemic, cancer testing decreased across all health systems and cancer types (range, 18%–96%). Overall, decreases in monthly rates were followed by rapid recovery to prepandemic rates. The rates of 6-month follow-up of abnormal screening results trended down in the COVID versus pre-COVID periods, as did the diagnosis of new cancers. Conclusions: Declines in cancer testing in the early months of the COVID-19 pandemic were short term, with at least short-term impacts on diagnostic follow-up and cancer diagnosis. The systems with the smallest decreases were those that both utilized remote screening outreach (e.g., mailed fecal immunochemical test kits) and did not pause that outreach at the start of the pandemic. Impact: Strategies and policies implemented by healthcare systems during public health emergencies can help minimize disruptions in care.
30 July 2025 in Journal of the Pediatric Infectious Diseases Society
Background: The cell culture-based inactivated influenza vaccine (ccIIV) was first approved for use in children aged 4-17 years in 2016 in the United States. The approved age indication for ccIIV was expanded to include children 6 months and older beginning the 2022-2023 season. There is limited real-world data on ccIIV effectiveness in children. We assessed ccIIV effectiveness using the test-negative design during the 2023-2024 season. Methods: Patients aged 6 months to 64 years who sought outpatient or telehealth care for acute respiratory illness were actively recruited between October 2023 and May 2024. Symptom eligibility criteria included cough, with an illness duration of ≤ 7 days. Respiratory samples were tested by reverse transcription polymerase chain reaction to identify influenza cases. Vaccination dates and products were determined by immunization records. Analyses were restricted to ccIIV recipients and unvaccinated participants. Cell culture-based inactivated influenza vaccine effectiveness was estimated as [100% × (1 − odds ratio)] for vaccination in cases versus test-negative controls, with adjustment for age and calendar time. Results: Among 1850 participants, 12% were age 6 months to 3 years, 32% were age 4-17 years, and 56% were age 18-64 years. Influenza was detected in 505 (27%) participants; 267 had influenza A/H1N1pdm09; 149 had influenza B; 56 had influenza A/H3N2; and 33 had influenza A with unknown subtype. A total of 470 (25%) received ccIIV. Among children (age 6 months to 17 years), ccIIV effectiveness was 64% [95% confidence interval (CI), 37%-81%] against influenza A/H1N1pdm09, 75% (95% CI, 43%-91%) against influenza B, and 76% (95% CI, 4%-97%) against influenza A/H3N2. Among adults (age 18-64 years), ccIIV effectiveness was 56% (95% CI, 31%-73%) against influenza A/H1N1pdm09, 62% (95% CI, 13%-86%) against influenza B, and 33% (95% CI, −62% to 76%) against influenza A/H3N2. Young children aged 6 months to 3 years had the highest point estimates (88%-98%). Conclusion: Cell culture-based inactivated influenza vaccine generated substantial real-world effectiveness against medically attended, laboratory-confirmed influenza in children and adults during a season when influenza A/H1N1pdm09 viruses predominated and influenza B and influenza A/H3N2 co-circulated at lower levels.
Background: Adults with high-risk conditions (underlying health conditions that increase risk of severe outcomes after respiratory infection) may have a substantial incidence of respiratory syncytial virus (RSV), but existing information on this topic is limited. We assessed the seasonal incidence of RSV in adults with high-risk conditions in a Wisconsin community. Methods: We conducted a retrospective study using data and respiratory specimens from participants with medically attended acute respiratory illness (MAARI) in a test-negative study of influenza vaccine effectiveness. We included individuals ≥18 years old in 2015–16 through 2019–20 seasons, with ≥1 high-risk condition. Residual respiratory specimens were retested for RSV using a multiplex viral panel. We calculated seasonal incidence using Poisson regression and population weighting, with the sum of observed and extrapolated RSV cases in the study cohort divided by the number of adults with high-risk conditions in the underlying source population. Results: Of 3601 respiratory samples tested, 97% were White and 66% were female. The mean (standard deviation) age of participants was 53 (19) years. We identified 303 RSV infections; 40% were RSV A. Estimated incidence of RSV-related MAARI was 94.1 (79.5–111.5) per 10 000 high-risk adults across all seasons and varied by season. Age-specific incidence per 10 000 was 69.3 (95% confidence interval [CI], 52.4–91.7) for those 18–49 years; 131.6 (95% CI, 92.3–187.6) for those 50–59 years; 109.9 (95% CI, 80.2–150.6) for those 60–74 years; and 150.5 (95% CI, 100.8–224.6) for those ≥75 years. Conclusions: Overall, these findings suggest a substantial incidence of RSV-related MAARI in adults with high-risk conditions.
17 July 2025 in Influenza and Other Respiratory Viruses
Background: The burden of human metapneumovirus (hMPV) among community‐dwelling high‐risk adults is understudied. We calculate the cumulative incidence of outpatient hMPV in high‐risk adults, over five consecutive winter respiratory virus seasons (2015–2016 through 2019–2020), and describe clinical characteristics of their illnesses.Methods: We conducted a retrospective analysis of data and respiratory specimens from adults ≥ 18 years old originally participating in a test‐negative study of influenza vaccine effectiveness. We included adults with ≥ 1 high‐risk condition in 2015–2016 through 2019–2020 seasons. Residual respiratory specimens were retested for hMPV using a multiplex viral panel. We calculated seasonal incidence using Poisson regression and population weighting, with the sum of observed and extrapolated hMPV cases in the study cohort divided by the number of adults with high‐risk conditions in the underlying source population.Results: We tested 3601 respiratory samples; the mean (SD) age of individuals contributing samples was 53 (19) years. We identified 289 individuals (8.0%) with a respiratory sample positive for human metapneumovirus. The estimated seasonal incidence of outpatient hMPV‐associated acute respiratory illness was 95.6 (95% CI: 80.5–113.4) cases per 10,000 high‐risk adults. These values varied by season, with the highest incidence in 2015–2016 (276.8 cases per 10,000; 95% CI: 210.7–363.5) and lowest in 2016–17 (55.0 cases per 10,000; 95% CI: 31.2–97.0).Conclusions: We identified substantial seasonal incidence of hMPV cases in community‐dwelling high‐risk adults in a Wisconsin population cohort.